Business
Tenaya Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Updates
- Initiated global natural history study for pediatric patients with MYBPC3 mutation to support clinical development of TN-201 gene therapy - Presented
About this update from Tenaya Therapeutics, Inc.
[{"type":"text","content":"\n- Initiated global natural history study for pediatric patients with MYBPC3 mutation to support clinical development of TN-201 gene therapy\n\n- Presented preclinical data supporting both TN-201 and PKP2 gene therapy programs at the European Society of Gene and Cell Therapy conference demonstrating significant and durable disease reversal and survival in severe murine models of disease\n\n- Initiated cGMP manufacturing to support the IND filing for TYA-11631 small molecule for HFpEF\n\n SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--\nTenaya Therapeutics, Inc. (NASDAQ: TNYA), a biotechnology company with a mission to discover, develop and deliver curative therapies that address the underlying causes of heart disease, today reported business and program updates and third quarter 2021 financial results.\n\n“The third quarter of 2021 was a significant marker in Tenaya’s history with the successful completion of our IPO, and it also represented a period of growth for the company as we continued to make progress on our key pipeline programs and operations,” said Faraz Ali, CEO of Tenaya. “We are pleased to announce the initiation of our global natural history study for pediatric patients with MYBPC3 mutations, as this supports our TN-201 gene therapy program as well as our evolution towards becoming a clinical-stage company. The initiation of cGMP manufacturing for TYA-11631 is an important operational milestone and another step in the direction of our vision for modality-agnostic drug discovery. The first-ever presentation of data supporting our PKP2 gene therapy program at an important scientific conference provides new hope for individuals and families fighting the leading genetic cause of Arrhythmogenic Right Ventricular Cardiomyopathy, a severe disease with high unmet need.”\n\nBusiness and Program Updates\n\n\nTN-201 – MYBPC3 Gene Therapy Program for Genetic HCM (gHCM):\n\n\nPre-clinical data on the treatment in a severe MYBPC3 mutant mouse model of gHCM with TN-201 demonstrating extended survival to 18 months after a single dose and continued improvement in functional measures was presented at the annual meeting of the European Society of Gene and Cell Therapy (ESGCT) in October 2021.\n\n\nTenaya has initiated a global natural history study to improve our understanding of disease progression and unmet need in individuals carr...